ASH 2013 - New Orleans - CML - Chronic Myeloid Leukemia
CML Program
Saturday, December 7, 2013
Chronic Myeloid Leukemia: Refining/Redefining the State of the Art
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster I
632. Chronic Myeloid Leukemia: Therapy: Poster I
Sunday, December 8, 2013
Use of Tyrosine Kinase Inhibitors in Myeloid Malignancies
632. Chronic Myeloid Leukemia: Therapy: Key Clinical Updates
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II
632. Chronic Myeloid Leukemia: Therapy: Poster II
Monday, December 9, 2013
632. Chronic Myeloid Leukemia: Therapy: Early Surrogate Markers of Outcome, Long-Term Treatment and Treatment Discontinuation
602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Molecular Mechanisms of Myeloid Leukemia
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Targeting Malignant Stem Cells and the Microenvironment in Chronic Myeloid Leukemia
632. Chronic Myeloid Leukemia: Therapy: Emerging Aspects of Monitoring and Long-Term Treatment
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III
632. Chronic Myeloid Leukemia: Therapy: Poster III
Tuesday, December 10, 2013
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Biologic Factors Impacting on Alternative Therapeutic Strategies in Chronic Myeloid Leukemia
NOTES
Abstracts and notes on CML presentations by Prof Steve O’Brien
2013, SPIRIT2, NewCastle Universisty
Forums and Patient associations'reports
CML Advocates Network presents their adherence survey at ASH 2013 - poster available for download
Patient Advocate Point of View at American Society of Hematology (ASH)
ASH Report #2: First-line trial updates, STOP trials, early switching, comorbidities, side effects
ASH 2013 by Cmlsupport (UK)
NEWS
Jorge E. Cortes, MD, and Michael J. Mauro, MD, provide expert perspective on the clinical implications of key study findings in chronic myeloid leukemia.
January 13, 2013, Clinical care options Oncology
Off and On Again Story of Ponatinib in CML – by Michael Deininger, reporting from ASH 2013
December 20, 2013, Medscape
Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia
December 17, 2013, News medical
Genetic Puzzle Piece for Blood Cancers Found
December 12, 2013, MedPage Today
Bristol-Myers Presents Long-term Data on Sprycel
December 10, 2013 , Zacks.com
Bristol-Myers Presents Long-term Data on Sprycel - Analyst Blog
December 10, 2013, NASDAQ
Positive Data on Novartis Tasigna
December 10, 2013 , Zacks.com
Phase III studies demonstrate superiority of Novartis' Tasigna over Glivec in newly diagnosed Ph+ CML patients
December 10, 2013, Pharmabiz.com
Preliminary Results from Bio-Path Holdings’ Phase I Clinical Trial Presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans
December 9, 2013, Business Wire
ARIAD Loses as EMA Deliberates on Iclusig - Analyst Blog
December 9, 2013, Zacks.com
Four-Year Data from Phase 3 DASISION Trial Comparing Sprycel® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Presented at ASH 2013
December 9, 2013, Business Wire
Excitement Over CAR-Engineered T-cells in Leukemia and Lymphoma
December 9, 2013, Medscape
SOME INTERESTING ABSTRACTS FOR CML
Vitamin D3 Analog Inecalcitol Synergizes with Imatinib To Inhibit Selectively The Growth Of Chronic Myeloid
Leukemia (CML) Progenitors and Stem Cells
Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms
The Genomic Landscape of Myeloproliferative Neoplasms: Somatic CALR Mutations in the Majority of JAK2-Wildtype Patients
Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia
Return to other ASH Annual Meetings
